<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189176</url>
  </required_header>
  <id_info>
    <org_study_id>2002-0806</org_study_id>
    <nct_id>NCT00189176</nct_id>
  </id_info>
  <brief_title>Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Phase I/II Trial of Tetrathiomolybdate (TM) in Patients With Usual Interstitial Pneumonia Refractory to Previous Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coalition for Pulmonary Fibrosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of the administration of a copper chelating agent,
      tetrathiomolybdate, for patients with idiopathic pulmonary fibrosis that have failed previous
      treatment. The primary endpoint for this study is safety with secondary endpoints including
      change in pulmonary function, exercise capacity, and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Tetrathiomolybdate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrathiomolybdate</intervention_name>
    <arm_group_label>Tetrathiomolybdate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic pulmonary fibrosis

          -  Disease progression despite six months of treatment (steroids with/without
             azathioprine or cyclophosphamide) defined by at least one of the following:

               -  Increased symptoms

               -  Decline in forced vital capacity of at least 10%

               -  Decline in diffusion capacity for carbon monoxide of at least 20%

               -  Increased infiltrate on CXR or high resolution CT scan

          -  Taking &lt; 15 mg prednisone for at least 30 days prior to screening

          -  Age 35-80, inclusive

          -  Able to understand a written informed consent and comply with the study protocol

        Exclusion Criteria:

          -  Significant environmental exposure

          -  Diagnosis of collagen vascular disease

          -  Evidence of active infection

          -  Clinically significant cardiac disease:

               -  Myocardial infarction, coronary artery bypass or angioplasty within 6mo

               -  Unstable angina pectoris

               -  Congestive heart failure requiring hospitalization within 6 months

               -  Uncontrolled arrhythmia

          -  Poorly controlled or severe diabetes mellitus

          -  Pregnancy or lactation

          -  Women of childbearing potential not using a medically approved means of contraception
             (i.e. oral contraceptives, intrauterine devices, diaphragm, Norplant)

          -  Current enrollment in another experimental protocol

        Physiologic Criteria:

          -  FEV1/FVC &lt; 0.60

        Laboratory Criteria:

          -  Total bilirubin &gt; 1.5 X upper limit normal

          -  AST or ALT &gt; 3X upper limit normal

          -  Alkaline phosphatase &gt; 3X upper limit normal

          -  White blood cell count &lt; 2,500/mm3

          -  Hematocrit &lt; 30%

          -  Platelets &lt; 100,000/mm3

          -  Prothrombin time INR &gt; 1.5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin R Flaherty, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>February 5, 2013</last_update_submitted>
  <last_update_submitted_qc>February 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Kevin R. Flaherty</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrathiomolybdate</mesh_term>
    <mesh_term>Molybdenum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

